Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma - Ariyasu, Hiroyuki; Inaba, Hidefumi; Ota, Takayuki; Yamaoka, Hiroyuki; Furukawa, Yasushi; Iwakura, Hiroshi; Doi, Naotaka; Yamamoto, Yuki; Akamizu, Takashi (In vivo (Athens), 2018)
Keywords: Adrenal Insufficiency - diagnosis; Adrenal Insufficiency - etiology; Antibodies; Antigens; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Autoimmune diseases; CTLA-4 Antigen - antagonists & inhibitors; Disease; Fatal Outcome; Female; Growth hormones; Humans; Hyponatremia; Hypothyroidism; Laboratories; Magnetic Resonance Imaging; Melanoma; Melanoma - complications; Melanoma - diagnosis; Melanoma - drug therapy; Middle Aged; Molecular Targeted Therapy - adverse effects; Molecular Targeted Therapy - methods; Pituitary gland; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Skin cancer; Thrombocytopenia; Thyroid Function Tests; Thyroid gland; Thyrotoxicosis - diagnosis; Thyrotoxicosis - etiology; Ultrasonography; malignant melanoma; ACTH; thyroid gland; CTLA-4; irAEs; pituitary gland; PD-1